Skip to content
TriangleGet started
← Study library

NCT03017326 · CITED IN SOURCE DOCUMENTS

Paediatric Hepatic International Tumour Trial

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-05-13

The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of HB\* and histologically defined diagnosis of HB or HCC. \*Histological confirmation of HB is required except in emergency situations where: * a) the patient meets all other eligibility criteria, but is too ill to undergo a biopsy safely, the patient may be enrolled without a biopsy. * b) there is anatomic or mechanical compromise of critical organ function by tumour (e.g., respiratory distress/failure, abdominal compartment syndrome, urinary obstruction, etc.) * c) Uncorrectable coagulopathy * Age ≤30 years * Written informed consent for trial entry Exclusion Criteria: * Any previous chemotherapy or currently receiving anti-cancer agents * Recurrent disease * Previously received a solid organ transplant; other than orthotopic liver transplantation (OLT). * Uncontrolled infection * Unable to follow or comply with the protocol for any reason * Second malignancy * Pregnant or breastfeeding women
healthy Volunteers
false
maximum Age
30 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
    intervention Names
    1. Drug: Cisplatin
    label
    Group A Very Low Risk HB
    type
    OTHER
  2. description
    Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
    intervention Names
    1. Drug: Cisplatin
    label
    Group B Low Risk HB
    type
    ACTIVE_COMPARATOR
  3. description
    Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Doxorubicin
    3. Drug: Carboplatin
    4. Drug: 5Fluorouracil
    5. Drug: Vincristine
    label
    Group C Intermediate Risk HB
    type
    ACTIVE_COMPARATOR
  4. description
    Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Doxorubicin
    3. Drug: Carboplatin
    4. Drug: Vincristine
    5. Drug: Etoposide
    6. Drug: Irinotecan
    label
    Group D High Risk HB
    type
    ACTIVE_COMPARATOR
  5. description
    Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Doxorubicin
    label
    Group E Resected HCC
    type
    OTHER
  6. description
    Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Doxorubicin
    3. Drug: Gemcitabine
    4. Drug: Oxaliplatin
    5. Drug: Sorafenib
    label
    Group F Unresected HCC
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Group A Very Low Risk HB
    2. Group B Low Risk HB
    3. Group C Intermediate Risk HB
    4. Group D High Risk HB
    5. Group E Resected HCC
    6. Group F Unresected HCC
    description
    Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
    name
    Cisplatin
    type
    DRUG
  2. arm Group Labels
    1. Group C Intermediate Risk HB
    2. Group D High Risk HB
    3. Group E Resected HCC
    4. Group F Unresected HCC
    description
    Arms C, D and E used in combination
    name
    Doxorubicin
    type
    DRUG
  3. arm Group Labels
    1. Group C Intermediate Risk HB
    2. Group D High Risk HB
    description
    Arms C and D used in combination
    name
    Carboplatin
    type
    DRUG
  4. arm Group Labels
    1. Group C Intermediate Risk HB
    description
    Arm C used alone
    name
    5Fluorouracil
    type
    DRUG
  5. arm Group Labels
    1. Group C Intermediate Risk HB
    2. Group D High Risk HB
    description
    Arms C and D used in combination
    name
    Vincristine
    type
    DRUG
  6. arm Group Labels
    1. Group D High Risk HB
    description
    Arm D used in combination
    name
    Etoposide
    type
    DRUG
  7. arm Group Labels
    1. Group D High Risk HB
    description
    Arm D used in combination
    name
    Irinotecan
    type
    DRUG
  8. arm Group Labels
    1. Group F Unresected HCC
    description
    Arm F used in combination
    name
    Gemcitabine
    type
    DRUG
  9. arm Group Labels
    1. Group F Unresected HCC
    description
    Arm F used in combination
    name
    Oxaliplatin
    type
    DRUG
  10. arm Group Labels
    1. Group F Unresected HCC
    description
    Arm used in combination
    name
    Sorafenib
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
FACTORIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
450
type
ESTIMATED
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Event-free survival (EFS) is defined as the time from randomisation (or registration into the trial for non-randomised patients) to first failure event. Patients who have not had an event will be censored at their last follow-up date. Failure events are: * progression of existing disease or occurrence of disease at new sites, * death from any cause prior to disease progression, * diagnosis of a second malignant neoplasm.
    measure
    Event-free survival (EFS)
    time Frame
    From date of randomisation (or registration into the trial for non-randomised patients), until date of first failure event, assessed up to 6 years.
  2. description
    Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria. The assessment will be performed after 3 cycles of PLADO, or 4 cycles of PLADO+S/GEMOX+S in Group F. Patients who are not assessable for response - e.g. because of early stopping of treatment or death - will be assumed to be non-responders.
    measure
    Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria
    time Frame
    From date of screening assessment until date of first response assessment, up to 63 days in Group F
secondary Outcomes
  1. description
    Failure-free survival (FFS) is defined as the time from randomisation (or registration into the trial for non-randomised patients) to first failure event. Patients who have not had an event will be censored at their last follow-up date. Failure events are: * progression of existing disease or occurrence of disease at new sites, * death from any cause prior to disease progression, * diagnosis of a second malignant neoplasm. failure to go to resection.
    measure
    Failure-free survival (FFS)
    time Frame
    From date of randomisation (or registration into the trial for non-randomised patients) until date of first failure event, or date of last follow up assessment, assessed up to 6 years.
  2. description
    Overall survival (OS) is defined as the time from randomisation (or registration for non-randomised patients) to death from any cause. Patients who have not died will be censored at their last follow-up date.
    measure
    Overall survival (OS)
    time Frame
    From date of randomisation (or registration for non-randomised patients) until date of death from any cause, or date of last follow up assessment, assessed up to 6 years.
  3. description
    Toxicity will be recorded in relation to each cycle of randomised treatment and will be categorized and graded using Common Terminology Criteria for Adverse Events (CTCAE)
    measure
    Toxicity categorized and graded using Common Terminology Criteria for Adverse Events (CTCAE)
    time Frame
    From date of start of randomised treatment until date 30 days after last treatment.
  4. description
    Chemotherapy-related cardiac, nephro- and oto-toxicity will be recorded in relation to each cycle of treatment and will be categorized and graded using Common Terminology Criteria for Adverse Events (CTCAE)
    measure
    Chemotherapy-related cardiac, nephro- and oto-toxicity using Common Terminology Criteria for Adverse Events (CTCAE)
    time Frame
    From date of start of randomised treatment until date 30 days after last treatment.
  5. description
    Hearing loss will be measured according to the SIOP Boston Scale for oto-toxicity. The assessment will be performed at end of treatment (EOT) and follow up
    measure
    Hearing loss according to the SIOP Boston Scale
    time Frame
    From date of registration until date of last follow up assessment, or date of death, assessed up to 6 years.
  6. description
    Best Response is defined as CR or PR and is based on radiological response (RECIST v1.1) and Alpha Fetoprotein (AFP) decline. Best Response will be measured throughout treatment period. Patients who are not assessable for response - e.g. because of early stopping of treatment or death - will be assumed to be non-responders.
    measure
    Best Response
    time Frame
    From date of first treatment until the date of last treatment, or until the date of first documented progression or date of death, assessed up to 6 months.
  7. description
    Surgical resectability is defined as complete resection, partial resection or transplant
    measure
    Surgical resectability defined as complete resection, partial resection or transplant
    time Frame
    From date of registration until date of last follow up assessment, or date of death, assessed up to 6 years.
  8. description
    Adherence to surgical guidelines is defined as the local clinician's surgical decision to resect or not compared to the current SIOPEL surgical guidelines.
    measure
    Adherence to surgical guidelines
    time Frame
    From date of registration until date of last follow up assessment, or date of death, assessed up to 6 years.
Full study description
brief Summary
The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.
detailed Description
The trial will evaluate whether reducing treatment for low risk HB patients maintains their excellent event free survival (EFS) and decreases acute and long-term toxicity. Intensification of therapy with the use of novel agents will be evaluated in the high risk group. The trial will also compare three different regimens in intermediate risk HB. Patients with HCC will be divided into groups based on whether the tumour is resectable or unresectable and/or metastatic. Evaluation of the biology of HB and HCC, using the identification/validation of novel and already reported prognostic biomarkers as well as toxicity biomarkers is a key strand of this trial, so patients in all risk groups can be registered. The trial is also designed to optimise the collection of clinically annotated biologic specimens and establish the world's largest repository of blood and tissue samples from paediatric patients with HB and HCC. The trial includes 4 randomised comparisons addressing therapeutic questions. For low risk HB patients, outcome with a total of 4 cycles of treatment is not inferior to those receiving a total of 6 cycles of treatment. For intermediate risk patients, 3 regimens will be compared for outcome and toxicity. For high risk patients, 2 post induction regimens will be compared for outcome. For resected HCC patients, the addition of GEMOX to PLADO regimen will be compared. In addition the following will be assessed: * To validate a new global risk stratification, defined by Children's Hepatic Tumours International Collaboration (CHIC) * To evaluate clinically relevant factors, including the following: * Provide a comprehensive and highly-validated panel of diagnostic and prognostic biomarkers * Determine if paediatric HCC is a biologically different entity to adult HCC * Develop genomic and/or biomarker analysis to predict children who may have an increased risk of developing toxicity with chemotherapy. * To establish a collection of clinically and pathologically-annotated biological samples. * Evaluate a surgical planning tool for an impact on decision making processes in POST-TEXT III and IV HB
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-5ed661d48815b55176f7
      requested nct id
      NCT03017326
      primary nct id
      NCT03017326
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      d1c4764cefac8f52386eb4980e6ce052c7fa381e5a566d4312d4554760d0b017
      payload sha256
      f34da4f1ff0106b885ab7f591f9140cad897558b9c66a9341f022ad7949700a6
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-5ed661d48815b55176f7
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT03017326
      occurrences
      1. context exact
        patoblastoma will require independent validation, which is one of the objectives of the Paediatric Hepatic International Tumour Trial (<a href="/clinicaltrials/NCT03017326">PHITT [NCT03017326]</a>).</p> </section> </section><section id="_2473"> <h3 id="_2473_toc">Hepatocellular Carcinoma</h3> <section id="_s
        end
        806691
        exact text
        NCT03017326
        start
        806680
      2. context exact
        quire independent validation, which is one of the objectives of the Paediatric Hepatic International Tumour Trial (<a href="/clinicaltrials/NCT03017326">PHITT [NCT03017326]</a>).</p> </section> </section><section id="_2473"> <h3 id="_2473_toc">Hepatocellular Carcinoma</h3> <section id="_sm_CDR0000795795_751"
        end
        806711
        exact text
        NCT03017326
        start
        806700
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/b5dc156ffd41aa11a5.html
      source file sha256
      d1c4764cefac8f52386eb4980e6ce052c7fa381e5a566d4312d4554760d0b017
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:38.429497+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      5b887c191cff63e452682b94a36f2f0fba68c8b5f3d708acb473b5c8b6453db5
      source title
      Childhood Cancer Genomics (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 30, 2025
        datetime
        2025-04-30T12:00:00Z
        display
        April 30, 2025
    2. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-a33d8e94dd9eabafa8f6
      requested nct id
      NCT03017326
      primary nct id
      NCT03017326
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      4c58da315c011c9fce366d0b3d1622f2faba78e750ad4739f89f83e6f040e2ad
      payload sha256
      f39f2c1dec66c88f6d3a201cd3f6515ec890bf14a10e603e141707b56a162d61
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-a33d8e94dd9eabafa8f6
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT03017326
      occurrences
      1. context exact
        patoblastoma will require independent validation, which is one of the objectives of the Paediatric Hepatic International Tumour Trial (<a href="/clinicaltrials/NCT03017326">PHITT [NCT03017326]</a>).</p> </section> </section><section id="_366"> <h3 id="_366_toc">Diagnosis</h3> <section id="_1877"> <h4
        end
        130312
        exact text
        NCT03017326
        start
        130301
      2. context exact
        quire independent validation, which is one of the objectives of the Paediatric Hepatic International Tumour Trial (<a href="/clinicaltrials/NCT03017326">PHITT [NCT03017326]</a>).</p> </section> </section><section id="_366"> <h3 id="_366_toc">Diagnosis</h3> <section id="_1877"> <h4 id="_1877_toc">Biop
        end
        130332
        exact text
        NCT03017326
        start
        130321
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/c6f6bd763c84dfcedd.html
      source file sha256
      4c58da315c011c9fce366d0b3d1622f2faba78e750ad4739f89f83e6f040e2ad
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:58.686488+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      0554ab85bc4581c08d95746555b5b04b1d456363c50e269b0dd2d07b4cf008c0
      source title
      Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: January 6, 2025
        datetime
        2025-01-06T12:00:00Z
        display
        January 6, 2025

    Preserved source evidence · Independent clinical review pending · Not medical advice